Table 1 |
||||
|
Histomorphometric results in rats treated with glucocorticoids (GC) and risedronate (Ris) |
||||
|
Controls |
Ris |
GC |
GC+Ris |
|
|
|
||||
|
Bone volume/tissue volume (%) |
35 ± 1 |
39 ± 1(b,c) |
31 ± 1(b) |
36 ± 1(a) |
|
Trabecular thickness (μm) |
50 ± 1 |
55 ± 1(b) |
43 ± 1(b) |
53 ± 1(a) |
|
Trabecular number (N/mm) |
3.4 ± 0.2 |
4.6 ± 0.1(b) |
2.9 ± 0.1(b) |
4.4 ± 0.1(a,b) |
|
Trabecular separation (μm) |
155 ± 6.5 |
139 ± 4.8(b,c) |
273 ± 5.3(b) |
144 ± 6.1(a) |
|
Mineral apposition rate (μm/day) |
0.66 ± 0.04 |
0.65 ± 0.04 |
0.62 ± 0.05(b) |
0.65 ± 0.04 |
|
Mineralized surface/BS (%) |
11.2 ± 1.5 |
9.8 ± 0.9(b) |
9.6 ± 0.9(b) |
9.8 ± 1.0(b) |
|
Bone formation rate/BS (μm3/μm2/day |
7.4 ± 1.2 |
6.3 ± 0.6(b) |
5.9 ± 0.6(b) |
6.3 ± 0.6(b) |
|
Wall thickness (μm) |
16.8 ± 1.3 |
24.9 ± 3.6(b) |
12.0 ± 3.1(b) |
22.8 ± 5.9(a,b) |
|
Activation frequency (N/yr) |
1.6 ± 0.3 |
0.9 ± 0.2(b) |
1.9 ± 0.6 |
1.0 ± 0.3(a,b) |
|
Active formation period (days) |
25.4 ± 2.0 |
38.8 ± 5.4(b) |
19.4 ± 4.8 |
35.3 ± 9.3(a,b) |
|
Eroded surface/BS (%) |
1.9 ± 1.0 |
1.7 ± 0.7 |
2.2 ± 1.1 |
1.9 ± 1.1 |
|
|
||||
|
BS, bone surface. a) P < 0.001 vs GC. b) P < 0.05/P < 0.001 vs controls. c) P < 0.001 vs GC + Ris. All values are expressed as mean ± SD. |
||||
|
Valenti et al. Arthritis Research & Therapy 2010 12:R163 doi:10.1186/ar3122 |
||||
